Iovance Biotherapeutics, Inc. (IOVA)

NASDAQ: IOVA · IEX Real-Time Price · USD

11.31

-0.41 (-3.50%)

At close: Apr 19, 2024, 4:00 PM

11.30

-0.01 (-0.09%)

After-hours: Apr 19, 2024, 7:31 PM EDT

Iovance Biotherapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2007
Net Income	-444.04	-395.89	-342.25	-259.58	-197.56	-123.58	-92.06	-102.35	-27.66	-12.04	Upgrade
Depreciation & Amortization	33.13	21.14	13.98	8.71	8.12	0.96	0.95	0.98	1	0.09	Upgrade
Share-Based Compensation	62.63	84.02	69.77	40.89	24.28	20.03	11.97	18.9	8.52	3.81	Upgrade
Other Operating Activities	-13.54	-2.02	30.57	4.85	6.27	1.35	0.44	0.34	-0.24	-0.5	Upgrade
Operating Cash Flow	-361.82	-292.76	-227.94	-205.13	-158.89	-101.25	-78.71	-32.67	-18.38	-8.63	Upgrade
Capital Expenditures	-22.29	-20.43	-37.57	-46.79	-6.92	-1.2	-1.03	-1.52	-1.14	-1.59	Upgrade
Acquisitions	-212.63	0	0	0	0	0	0	0	0	0	Upgrade
Change in Investments	79.68	276.88	37.71	-271.06	96.94	-385.08	59.71	10.42	-70.07	0	Upgrade
Investing Cash Flow	-155.24	256.46	0.13	-317.85	90.03	-386.28	58.68	8.89	-71.21	-1.59	Upgrade
Share Issuance / Repurchase	465.75	192.8	238.27	576.71	6.44	424.53	6.28	1.86	9.96	3.22	Upgrade
Debt Issued / Paid	0	0	1	0	0	0	0	0	0	0	Upgrade
Other Financing Activities	-2.8	-2.65	-	-0.28	-0.31	-0.22	52.41	95.04	68.31	32.24	Upgrade
Financing Cash Flow	462.96	190.15	239.27	576.42	6.13	424.31	58.69	96.9	78.27	35.46	Upgrade
Exchange Rate Effect	-2.74	0	0	0	0	0	0	0	0	0	Upgrade
Net Cash Flow	-56.84	153.85	11.46	53.44	-62.73	-63.22	38.66	73.13	-11.32	25.24	Upgrade
Free Cash Flow	-384.11	-313.18	-265.52	-251.93	-165.81	-102.45	-79.74	-34.19	-19.52	-10.23	Upgrade
Free Cash Flow Margin	-32305.30%	-	-	-	-	-	-	-	-	-	Upgrade
Free Cash Flow Per Share	-1.63	-1.97	-1.73	-1.82	-1.33	-1.05	-1.22	-0.62	-0.44	-0.41	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).